{
  "url": "https://openlegislation.uk/supply-and-appropriation-anticipation-and-adjustments-act-2024/schedule-2",
  "json_url": "https://openlegislation.uk/supply-and-appropriation-anticipation-and-adjustments-act-2024/schedule-2.json",
  "legislation": "ukpga/2024/4",
  "legislation_title": "Supply and Appropriation (Anticipation and Adjustments) Act 2024",
  "legislation_url": "https://openlegislation.uk/supply-and-appropriation-anticipation-and-adjustments-act-2024",
  "path": "schedule/2",
  "kind": "schedule",
  "number": "2",
  "heading": "Appropriation of excesses for financial year 2022-23",
  "text": "Department of Health and Social Care, 2022-23\nDepartment of Health and Social Care\nEstimate\nNet resources authorised for current purposes\nNet resources authorised for capital purposes\nNet Cash Requirement\n(£)\n(£)\n(£)\nDepartment of Health and Social Care\nDepartmental Expenditure Limit\n946,445,000\n0\nAnnually Managed Expenditure\n0\n0\nNon-budget Expenditure\n0\nNet Cash Requirement\n0\nTotal\n946,445,000\n0\n0\nDepartmental Expenditure Limit\nExpenditure arising from:\nRevenue (administration and programme) and capital expenditure of the Department of Health and Social Care and other designated bodies, including the NHS Commissioning Board, known as NHS England, (including Clinical Commissioning Groups), NHS Providers, Special Health Authorities, Executive Non-Departmental Public Bodies, the UK Health Security Agency and the Medicines and Healthcare products Regulatory Agency.\nHealth and social service expenditure to and on behalf of the NHS including the settlement of claims for personal injury and clinical negligence, local authorities and other national bodies.\nLocal government services, prison health services, medical, scientific and technical services, services for disabled persons, education and training, grants to voluntary organisations and other bodies, information services, breast implant registry, Healthy Start programme, health promotion activities, research and development, expenditure incurred in relation to life sciences and EU Exit.\nGovernmental response to the coronavirus Covid-19 pandemic. This includes, but is not exhaustive: NHS Test and Trace, personal protective equipment, Covid-19 medicines, treatments and equipment and the supply, distribution and deployment of Covid-19 vaccines and associated activities.\nNon-departmental public bodies' expenditure on health and social care protection, training and regulation functions.\nExpenditure to charitable trusts and companies providing financial support and other relief to persons who contracted HIV and Hepatitis C through receiving NHS treatment.\nForming, investing in or providing loans or guarantees to companies that will provide facilities or services to the NHS.\nServices provided to or on behalf of devolved governments and other government departments.\nMedical treatment given to people from the United Kingdom in the European Economic Area and other countries.\nSubsidies and grants to public corporations and local authorities, payments to local authorities for use in local area agreements. Official Development Assistance projects and activities.\nSubscriptions to international organisations and international and commercial facilitation relating to healthcare.\nPayments for services incurred by other government departments, including expenditure on behalf of the Department for Work and Pensions.\nAssociated depreciation and any other non-cash costs (including provisions, impairments and impairment of receivables).\nExpenditure incurred in relation to the Covid-19 Vaccine Taskforce.\nIncome arising from:\nCharges for accommodation, sales of goods and services, income generation schemes. Local authorities under joint financing arrangements. Fines and penalty notices. Medical and dental education levy. Licensing of software, use of NHS logo, settlement of legal claims, dividends and interest from loans and investments, intellectual property, research and development, prescription fraud charges, NHS prescriptions, dental and ophthalmic fraud charges.\nRecoveries from patients in respect of incorrect claims for eligibility including for NHS treatment and general ophthalmic services. Payments from manufacturers or suppliers of medicinal products to control the cost of health service medicines and purchasing and supply agency arrangements.\nSales of medicines, vaccines, antivenoms, antitoxins and equipment, premiums applied to the sale of stock.\nIncome from the Scottish Government, the Welsh Government, Northern Ireland, Channel Islands and Isle of Man for services provided for devolved or reserved work.\nProvision of policy and advice to other countries and care trusts. Maintenance of the National Joint Registry, conference and meeting events, prison health services, contributions to substance misuse funding, use of radio communication bandwidth.\nIncome secured by counter fraud services from all sources.\nAdministration income from seconded officers, cost of legal proceedings, staff telephone calls, European fast stream programme. Recoveries and income from other government departments, recoveries and income from ALBs (including capital and grants), special health authorities and NHS bodies. Selling services into wider markets and open government, payment by commercial tenants in DHSC buildings and compensation income.\nLicence fees and royalties, sales of publications, contributions by members of the public, insurance claims and social exclusion programmes. Other European Economic Area countries for NHS treatment of their residents. Income collected for the immigration health surcharge.\nSales of subsidised dried milk. Income from the European Union.\nContributions from the mobile phone industry, charitable contributions, refunds from voluntary organisations. Contributions to local authority grant schemes. Contributions and refunds towards communication campaigns contracts. Penalty charges, interest and dividends on trading fund loans. Income collected on behalf of health innovation and education clusters.\nIncome received from the sale of capital assets. Income received from the disposal of financial assets. Income associated with the acquisition of assets.\nIncome arising from Governmental response to the coronavirus Covid-19 pandemic.\nIncome arising from activities in relation to the Covid-19 Vaccine Taskforce and Covid-19 Antiviral Taskforce.",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/ukpga/2024/4/schedule/2",
    "retrieved_at": "2026-10-29T08:48:27.595562+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}